- |||||||||| BI 765063 / Boehringer Ingelheim, BI 770371 / Boehringer Ingelheim, OSE Immunotherapeutics, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov) - Nov 3, 2023 P1, N=12, Recruiting, Trial completion date: Nov 2025 --> Jan 2025 | Trial primary completion date: Mar 2025 --> Jul 2024 N=22 --> 12 | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
|